Breast Cancer Clinical Trial Using 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC

- The folks at University of Virginia are studying the effects of 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC on Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start July 2012.

434-982-1902
Emily Allred, PhD
Overall Study Contact Info
StatusName Contact Phone
RecruitingEmily Allred, PhDEH4M@virginia.edu434-982-1902

This study is officially titled, "A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage IB-IIIA Breast Cancer."

Locations

University of Virginia Health System

Charlottesville, Virginia - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.